Correlation Between Plasma NLRP3, IL-1β, and IL-18 and Diabetic Nephropathy in Patients With Type 2 Diabetes

被引:3
|
作者
Yuan, Yangyang [1 ]
Li, Liqin [1 ]
Wang, Xiaoyan [1 ]
Zhang, Pu [1 ]
Wang, Jun [1 ]
Xiao, Yanxin [1 ]
机构
[1] Baoding 1 Cent Hosp, Dept Endocrinol, Baoding, Hebei, Peoples R China
关键词
PATHOGENESIS;
D O I
暂无
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Context center dot Diabetic nephropathy (DN) is a common microvascular complication in diabetic patients. The pathogenesis of DN is complex. Inflammatory response may play a key role as a common downstream pathway. Objective center dot The study intended to explore the relationship between the levels of plasma nucleotide-binding oligomeric domain-like receptor protein 3 (NLRP3 inflammasome), interleukin-1 beta (IL-1 beta), and IL-18 and the progression of type 2 diabetic nephropathy to clarify their relationship with type 2 diabetes mellitus (T2DM) and to provide evidence for clinical treatment. Design center dot The research team performed a controlled observational study. Setting center dot The study took place at Baoding No. 1 Central Hospital in Baoding, Hebei, China. Participants center dot Participants were 153 patients with T2DM who received treatment at the hospital between October 2020 and October 2021. The research team allocated 30 participants without evidence of DN to the control group. Based on the DN stage, the team assigned the 123 remaining participants to one of five observation groups: (1) 32 participants with stage 1 DN to the DN1 group, (2) 31 participants with stage 2 DN to the DN2 group, (3) 30 participants with stage 3 DN to the DN3 group, (4) 30 participants with stage 4 DN to the DN4 group, and (5) 29 participants with stage 5 DN to the DN5 group. Outcome Measures center dot The research team measured participants' levels of "nucleotide binding oligomeric domain-like receptor protein 3" (NLRP3), interleukin-1 beta (IL-1 beta), and IL-18 and used the Spearman rank correlation analysis to determine the correlation between those levels and the DN stages. Results center dot The levels of NLRP3, IL-1 beta and IL-18 in all the five observation groups were significantly higher than those in the control group (all P <.01). The levels were also significantly higher: (1) in the DN2, DN3, DN4, and DN5 groups than those in the DN1 group (all P <.01); (2) in the DN3, DN4, and DN5 groups than those in the DN2 group (all P <.01); (3) in the DN4 and DN5 groups than those in the DN3 group (all P <.01); and (4) in the DN5 groups than those in the DN4 group (all P <.01). The Spearman rank correlation analysis showed that the NLRP3, IL-1 beta, and IL-18 levels were significantly positively correlated with the DN stage (P =.01). Conclusions center dot NLRP3, IL-1 beta and IL-18 played an important role in the progression of T2DM, and their levels increased with the aggravation of DN. Therefore, the plasma levels of NLRP3, IL-1 beta and IL-18 can be useful as indicators of the occurrence and development of DN and can provide clinical guidance for the early diagnosis of DN and for the determination and adjustment of treatment plans.
引用
收藏
页码:52 / 56
页数:5
相关论文
共 50 条
  • [21] Elevated intracranial pressure induces IL-1β and IL-18 overproduction via activation of the NLRP3 inflammasome in microglia of ischemic adult rats
    Ding, Hongguang
    Li, Ya
    Wen, Miaoyun
    Liu, Xinqiang
    Han, Yongli
    Zeng, Hongke
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2021, 47 (01) : 183 - 194
  • [22] NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis
    Grebe, Alena
    Hoss, Florian
    Latz, Eicke
    CIRCULATION RESEARCH, 2018, 122 (12) : 1722 - 1740
  • [23] Analysis of serum interleukin(IL)-1α, IL-1β and IL-18 in patients with systemic sclerosis
    Lin, Emily
    Vincent, Fabien B.
    Sahhar, Joanne
    Ngian, Gene-Siew
    Kandane-Rathnayake, Rangi
    Mende, Rachel
    Morand, Eric F.
    Lang, Tali
    Harris, James
    CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2019, 8 (04)
  • [24] Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes
    Seth L Masters
    Aisling Dunne
    Shoba L Subramanian
    Rebecca L Hull
    Gillian M Tannahill
    Fiona A Sharp
    Christine Becker
    Luigi Franchi
    Eiji Yoshihara
    Zhe Chen
    Niamh Mullooly
    Lisa A Mielke
    James Harris
    Rebecca C Coll
    Kingston H G Mills
    K Hun Mok
    Philip Newsholme
    Gabriel Nuñez
    Junji Yodoi
    Steven E Kahn
    Ed C Lavelle
    Luke A J O'Neill
    Nature Immunology, 2010, 11 : 897 - 904
  • [25] Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes
    Masters, Seth L.
    Dunne, Aisling
    Subramanian, Shoba L.
    Hull, Rebecca L.
    Tannahill, Gillian M.
    Sharp, Fiona A.
    Becker, Christine
    Franchi, Luigi
    Yoshihara, Eiji
    Chen, Zhe
    Mullooly, Niamh
    Mielke, Lisa A.
    Harris, James
    Coll, Rebecca C.
    Mills, Kingston H. G.
    Mok, K. Hun
    Newsholme, Philip
    Nunez, Gabriel
    Yodoi, Junji
    Kahn, Steven E.
    Lavelle, Ed C.
    O'Neill, Luke A. J.
    NATURE IMMUNOLOGY, 2010, 11 (10) : 897 - U1501
  • [26] Association Between IL-18 and Carotid Intima-Media Thickness in Patients with Type II Diabetic Nephropathy
    Zhang, Yuanyuan
    Feng, Haomiao
    Wei, Zhiyong
    MEDICAL SCIENCE MONITOR, 2017, 23 : 470 - 478
  • [27] 牙周炎患者血清及龈沟液NLRP3 mRNA,IL-18,IL-1β的变化及临床意义
    陶培
    冯晓伟
    赵燕霞
    实验与检验医学, 2023, 41 (03) : 258 - 261
  • [28] 高糖通过激活NLRP3炎症小体促进胎盘滋养细胞IL-1β、IL-18的释放
    胡天晓
    王秀景
    阮芸
    姚佳琦
    王凤玫
    徐永君
    王静
    谭擎缨
    中华内分泌代谢杂志, 2022, 38 (01) : 36 - 41
  • [29] Lipopolysaccharide/adenosine triphosphate induces IL-1β and IL-18 secretion through the NLRP3 inflammasome in RAW264.7 murine macrophage cells
    Xie, Qiag
    Shen, Wen-Wen
    Zhong, Jian
    Huang, Cheng
    Zhang, Lei
    Li, Jun
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2014, 34 (01) : 341 - 349
  • [30] 高血压脑出血患者外周血NLRP3及IL-1β和IL-18水平与预后的关系
    林存山
    杨晓莉
    候清
    李成熊
    孙斌
    西部医学, 2020, 32 (06) : 854 - 858